

第1号

出典：米国等において市販（要処方箋）されているメトロゲル、メトロ
クリームの写真および添付文書

① メトロクリーム 45g (メトロニダゾール 0.75%)
 ガルフェルマ

Metrocream
 Metronidazole Cream 0.75%
 (45g)

Indications: Metrocream is indicated for the treatment of bacterial vaginosis, trichomoniasis, and other infections of the genital tract caused by anaerobic bacteria and protozoa.

Contraindications: Metrocream should not be used in patients with known hypersensitivity to metronidazole or any of the excipients.

Warnings: Metrocream should be used with caution in patients with liver disease, as metronidazole is primarily excreted in the urine. Patients should be advised to avoid alcohol during treatment and for 48 hours after the last dose.

Side Effects: Common side effects include headache, dizziness, and metallic taste. In rare cases, peripheral neuropathy and seizures may occur.

Pharmacokinetics: Metrocream is a topical preparation. The active ingredient, metronidazole, is absorbed through the mucous membranes of the genital tract.



② メトロゲル 45g (メトロニダゾール 0.75%)
 ガルフェルマ

MetroGel
 Metronidazole Gel 0.75%
 (45g)

Indications: MetroGel is indicated for the treatment of bacterial vaginosis, trichomoniasis, and other infections of the genital tract caused by anaerobic bacteria and protozoa.

Contraindications: MetroGel should not be used in patients with known hypersensitivity to metronidazole or any of the excipients.

Warnings: MetroGel should be used with caution in patients with liver disease. Patients should be advised to avoid alcohol during treatment and for 48 hours after the last dose.

Side Effects: Common side effects include headache, dizziness, and metallic taste. In rare cases, peripheral neuropathy and seizures may occur.

Pharmacokinetics: MetroGel is a topical preparation. The active ingredient, metronidazole, is absorbed through the mucous membranes of the genital tract.



MetroCream™


(metronidazole topical cream)

Topical Cream, 0.75%

FOR TOPICAL USE ONLY
(NOT FOR OPHTHALMIC USE)

DESCRIPTION:

METROCREAM™ Topical Cream contains metronidazole, USP, at a concentration of 7.5 mg per gram (0.75%) in an emollient cream consisting of emulsifying wax, sorbitol solution, glycerin, isopropyl palmitate, benzyl alcohol, lactic acid and/or sodium hydroxide to adjust pH, and purified water. Metronidazole is a member of the imidazole class of anti-bacterial agents and is classified therapeutically as an antiprotozoal and anti-bacterial agent. Chemically, metronidazole is 2-methyl-5-nitro-1*H*-imidazole-1-ethanol. The molecular formula is C₆H₉N₃O₃ and molecular weight is 171.16. Metronidazole is represented by the following structural formula:



CLINICAL PHARMACOLOGY:

The mechanisms by which metronidazole acts in the treatment of rosacea are unknown, but appear to include an anti-inflammatory effect.

INDICATIONS AND USAGE:

METROCREAM (metronidazole topical cream) Topical Cream is indicated for topical application in the treatment of inflammatory papules and pustules of rosacea.



CONTRAINDICATIONS:

METROCREAM™ (metronidazole topical cream) Topical Cream is contraindicated in individuals with a history of hypersensitivity to metronidazole, or other ingredients of the formulation.

PRECAUTIONS:

General: Topical metronidazole has been reported to cause tearing of the eyes. Therefore, contact with the eyes should be avoided. If a reaction suggesting local irritation occurs, patients should be directed to use the medication less frequently or discontinue use. Metronidazole is a nitroimidazole and should be used with care in patients with evidence of, or history of blood dyscrasia.

Information for patients: This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.

Drug interactions: Oral metronidazole has been reported to potentiate the anticoagulant effect of warfarin and coumarin anticoagulants, resulting in a prolongation of prothrombin time. The effect of topical metronidazole on prothrombin time is not known.

Carcinogenesis, mutagenesis, impairment of fertility: Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats but not in studies involving hamsters.

Metronidazole has shown evidence of mutagenic activity in several *in vitro* bacterial assay systems. In addition, a dose-response increase in the frequency of micronuclei was observed in mice after intraperitoneal injections and an increase in chromosome aberrations have been reported in patients with Crohn's disease who were treated with 200-1200 mg/day of metronidazole for 1 to 24 months. However, no excess chromosomal aberra-

tions in circulating human lymphocytes have been observed in patients treated for 8 months.

Pregnancy: Teratogenic effects: Pregnancy category B There are no adequate and well-controlled studies with the use of METROCREAM™ (metronidazole topical cream) Topical Cream in pregnant women. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral metronidazole in rats or mice. However, because animal reproduction studies are not always predictive of human response and since oral metronidazole has been shown to be a carcinogen in some rodents, this drug should be used during pregnancy only if clearly needed.

Nursing mothers: After oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. Even though blood levels are significantly lower with topically applied metronidazole than those achieved after oral administration of metronidazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric use: Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS:

In controlled clinical trials, the total incidence of adverse reactions associated with the use of METROCREAM Topical Cream was approximately 10%. Skin discomfort (burning and stinging) was the most frequently reported event followed by erythema, skin irritation, pruritus and worsening of rosacea. All individual events occurred in less than 3% of patients.

The following additional adverse experiences have been reported with the topical use of metronidazole: dryness, transient redness, metallic taste, tingling or numbness of extremities and nausea.

DOSAGE AND ADMINISTRATION:

Apply and rub in a thin layer of METROCREAM™ (metronidazole topical cream) Topical Cream twice daily, morning and evening, to entire affected areas after washing.

Areas to be treated should be washed with a mild cleanser before application. Patients may use cosmetics after application of METROCREAM Topical Cream.

HOW SUPPLIED:

METROCREAM (metronidazole topical cream) Topical Cream, 0.75% is supplied in a 45 g aluminum tube - NDC 0299-3836-45.

Storage conditions: STORE AT CONTROLLED ROOM TEMPERATURE: 59° to 86°F (15° to 30°C).

Caution: Federal law prohibits dispensing without prescription.

GALDERMA

Marketed by:
GALDERMA Laboratories, Inc.
Fort Worth, Texas 76133 USA
Manufactured by:
DPT Laboratories, Inc.
San Antonio, Texas 78215 USA
GALDERMA is a registered trademark.
225029-0695
Revised: June 1995

MetroGel®

(metronidazole topical gel)

Topical Gel, 0.75%


FOR TOPICAL USE ONLY

(NOT FOR OPHTHALMIC USE)

DESCRIPTION:

METROGEL® Topical Gel contains metronidazole, USP, at a concentration of 7.5 mg per gram (0.75%) in a gel consisting of purified water, methylparaben, propylparaben, propylene glycol, carbomer 940, sodium hydroxide, and edetate disodium.

Metronidazole is classified therapeutically as an antiprotozoal and anti-bacterial agent. Chemically, metronidazole is named 2-methyl-5-nitro-1*H*-imidazole-1-ethanol and has the following structure:



CLINICAL PHARMACOLOGY:

Bioavailability studies on the topical administration of 1 gram of METROGEL Topical Gel (7.5 mg of metronidazole) to the face of 10 rosacea patients showed a maximum serum concentration of 66 nanograms per milliliter in one patient. This concentration is approximately 100 times less than concentrations afforded by a single 250 mg oral tablet. The serum metronidazole concentrations were below the detectable limits of the assay at the majority of time points in all patients. Three of the patients had no detectable serum concentrations of metronidazole at any time point. The mean dose of

gel applied during clinical studies was 600 mg which represents 4.5 mg of metronidazole per application. Therefore, under normal usage levels, the formulation affords minimal serum concentrations of metronidazole. The mechanisms by which METROGEL (metronidazole topical gel) Topical Gel acts in the treatment of rosacea are unknown, but appear to include an anti-inflammatory effect.

INDICATIONS AND USAGE:

METROGEL Topical Gel is indicated for topical application in the treatment of inflammatory papules and pustules of rosacea.

CONTRAINDICATIONS:

METROGEL Topical Gel is contraindicated in individuals with a history of hypersensitivity to metronidazole, parabens, or other ingredients of the formulation.

PRECAUTIONS:

General: METROGEL Topical Gel has been reported to cause tearing of the eyes. Therefore, contact with the eyes should be avoided. If a reaction suggesting local irritation occurs, patients should be directed to use the medication less frequently or discontinue use. Metronidazole is a nitroimidazole and should be used with care in patients with evidence of, or history of blood dyscrasia.

Information for patients: This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.

Drug interactions: Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin resulting in a prolongation of prothrombin time. The effect of topical metronidazole on prothrombin time is not known.

Carcinogenesis, mutagenesis, impairment of fertility:

Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats but not in studies involving hamsters.



Metronidazole has shown evidence of mutagenic activity in several *in vitro* bacterial assay systems. In addition, a dose-response increase in the frequency of micronuclei was observed in mice after intraperitoneal injections and an increase in chromosome aberrations have been reported in patients with Crohn's disease who were treated with 200-1200 mg/day of metronidazole for 1 to 24 months. However, no excess chromosomal aberrations in circulating human lymphocytes have been observed in patients treated for 8 months.

Pregnancy: *Teratogenic effects: Pregnancy category B:*

There has been no experience to date with the use of METROGEL (metronidazole topical gel) Topical Gel in pregnant patients. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral metronidazole in rats or mice. However, because animal reproduction studies are not always predictive of human response and since oral metronidazole has been shown to be a carcinogen in some rodents, this drug should be used during pregnancy only if clearly needed.

Nursing mothers: After oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. Even though METROGEL Topical Gel blood levels are significantly lower than those achieved after oral metronidazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric use: Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS:

The following adverse experiences have been reported with the topical use of metronidazole: burning, skin irritation, dryness, transient redness, metallic taste, tingling or numbness of extremities and nausea.

DOSAGE AND ADMINISTRATION:

Apply and rub in a thin film of METROGEL Topical Gel twice daily, morning and evening, to entire affected areas after washing.

Areas to be treated should be cleansed before application of METROGEL (metronidazole topical gel) Topical Gel. Patients may use cosmetics after application of METROGEL Topical Gel.

HOW SUPPLIED:

METROGEL (metronidazole topical gel) Topical Gel is supplied in a 1 oz. (28.4 g) aluminum tube – **NDC 0299-3835-28** and a 45 g aluminum tube – **NDC 0299-3835-45**.

Storage conditions: STORE AT CONTROLLED ROOM TEMPERATURE: 59° to 86°F (15° to 30°C).

Caution: Federal law prohibits dispensing without prescription.

GALDERMA 

Marketed by:
GALDERMA Laboratories, Inc., Fort Worth, Texas 76133 USA
Manufactured by: DPT Laboratories, Inc.
San Antonio, Texas 78215 USA
GALDERMA is a registered trademark.

225032-0895

Revised: August 1995